MicroRNA Signature in Renal Cell Carcinoma

Soudeh Ghafouri-Fard, Zeinab Shirvani-Farsani, Wojciech Branicki, Mohammad Taheri

  • Affiliations

    • 1Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
    • 2Department of Cell and Molecular Biology, Faculty of Life Sciences and Technology, Shahid Beheshti University G.C., Tehran, Iran.
    • 3Malopolska Centre of Biotechnology of the Jagiellonian University, Kraków, Poland.
    • 4Urogenital Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

    Free PMC article


Renal cell carcinoma (RCC) includes 2.2% of all diagnosed cancers and 1.8% of cancer-related mortalities. The available biomarkers or screening methods for RCC suffer from lack of sensitivity or high cost, necessitating identification of novel biomarkers that facilitate early diagnosis of this cancer especially in the susceptible individuals. MicroRNAs (miRNAs) have several advantageous properties that potentiate them as biomarkers for cancer detection. Expression profile of miRNAs has been assessed in biological samples from RCC patients. Circulatory or urinary levels of certain miRNAs have been proposed as markers for RCC diagnosis or follow-up. Moreover, expression profile of some miRNAs has been correlated with response to chemotherapy, immunotherapy or targeted therapeutic options such as sunitinib. In the current study, we summarize the results of studies that assessed the application of miRNAs as biomarkers, therapeutic targets or modulators of response to treatment modalities in RCC patients.

Keywords: biomarker; cancer; expression; miRNA; renal cell carcinoma.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.


Figure 1